
Food & Beverages

Carlsberg

Bloomherg

Price DKK628.50

Bloomberg CARLB D Reuters CARCb.CC 12-month High / Low (DKK) 679.0 / 490. Market Cap (DKKm) 96,27 Ev (BG Estimates) (DKKm) 141,33 Avg. 6m daily volume (000) 265. 3y EPS CAGR 6.99				
	1 M	3 M	6 M 31	/12/15
Absolute perf.	-2.2%	1.8%	3.8%	2.6%
Food & Bev.	0.2%	5.4%	6.8%	0.5%
DJ Stoxx 600	0.8%	1.9%	4.2%	-7.0%
YEnd Dec. (DKKm)	2015	2016e	2017e	2018e
Sales	65,354	63,522	65,637	67,289
% change		-2.8%	3.3%	2.5%
EBITDA	12,614	12,276	12,879	13,392
EBIT	7,940	7,602	8,304	8,899
% change		-4.3%	9.2%	7.2%
Net income	4,557	4,439	5,108	5,561
% change		-2.6%	15.1%	8.9%
	2015	2016e	2017e	2018e
Operating margin	12.1	12.0	12.7	13.2
Net margin	7.0	7.0	7.8	8.3
ROE	10.5	9.4	10.1	10.1
ROCE	5.5	5.3	6.3	6.8
Gearing	79.9	62.1	47.9	36.0
(DKK)	2015	2016 e	2017e	2018e
EPS	29.87	29.10	33.49	36.45
% change	-	-2.6%	15.1%	8.9%
P/E	21.0x	21.6x	18.8x	17.2x
FCF yield (%)	7.7%	5.0%	6.7%	6.3%
Dividends (DKK)	6.48	6.48	6.80	7.14
Div yield (%)	1.0%	1.0%	1.1%	1.1%
EV/Sales	2.2x	2.2x	2.1x	1.9x
EV/EBITDA	11.5x	11.5x	10.6x	9.8x
EV/EBIT	18.2x	18.6x	16.4x	14.7x



No Pernille

CARLB DC

Fair Value DKK600 (-5%)

We are updating our estimates for the next three years and are mainly lowering our 2016 figure given higher than expected marketing costs for the Euro football championship.

SELL

Last week, Carlsberg published slightly disappointing results disconnected from the recent share price increase, therefore prompting us to downgrade the stock to Sell (from Neutral). Today we are fine-tuning our model to take into account these recent results and trends. We are lowering our operating profit forecast for this year by 2%, mainly because of higher marketing costs linked to the Euro football championship. However for 2017 and 2018, our forecasts remain unchanged.

ANALYSIS

- Margins are down, not up. While the company had been showing off with significant margin expansion in each of the regions (Western Europe +70bp, Eastern Europe +100bp, Asia +60bp), the reality is slightly different. Marketing costs for the Euro football championship and costs for the strategic development and efficiency programmes are accounted for under non-allocated central costs (whereas their benefits are booked under regional profits). Overall group operating margin declined by 10bp to 11.0% from 11.1%.
- Savings? What savings? As the company is embarking on its efficiency improvement programme with a total budgeted DKK1.5 to DKK2.0bn efficiency improvements by 2018, a quarter of these improvements should be generated in 2016 and would be mainly savings (as opposed to investments), but with first half operating margin narrowing by 10bp and also by 10bp for the full year on our estimates, the savings are nowhere in sight. This is no genuine surprise. Indeed, we note that brewers (not just Carlsberg) need to save about 50-80bp of revenues p.a. to fund normal sales efforts (price or marketing). However, next year, we are looking for the company to step up its efficiency improvements to 160bp of revenue (vs 80bp this year) and would expect some of that to be visible in profit growth (assuming no currency drag).
- Russian pain not over. From 1st July, urban retailers need to connect to UFAIS (Unified Federal Automated Information System) and Carlsberg assumes that some of these retailers will not want to make the investment (on 1st July 2017, retailers in rural areas will also need to connect) and that volumes might be impacted. Moreover, as of 1st January 2017, brewers will no longer sell beer in PET bottles of more than 1.5l (around a quarter of total beer consumption) and this is expected to impact beer volumes by about 10%. Since brewers (and also Carlsberg) are likely to stop producing these bottles in Q4, Carlsberg is expecting its Russian beer volumes to decline by 5% in H2 2016 (after a flat H1 2016). But with the full impact of the PET 1.5l+ ban to come in 2017, Russian beer volumes are likely to decline by a further 5% in 2017 (according to our estimates).
- Quick de-levering will lead to new acquisitions. Over the last 12 months plenty has been done to clean up assets with 11 breweries already sold/closed in China and more to come with the sales of a Danish malting business, a Vietnamese greenfield and the Malawi operations. Furthermore, capex has been reined in and trade working capital was already -7.5% of revenues by the end of the first half of 2016. As such, we expect the company to close 2016 with a net debt/EBITDA of 2.1 vs 2.5 at the end of 2015 and believe that an improvement to 1.6x by the end of 2017 is possible. We believe this could trigger renewed interest in acquiring assets.

VALUATION

• Our fair value of DKK600 is based on a risk free rate of 1.6%, a risk premium of 7%, a beta of 0.95 and a long term growth rate of 3.5%

NEXT CATALYSTS

9th November 2016: Q3 trading statement

Click here to download document



Analyst: Nikolaas Faes 33(0) 6 11 12 44 44 nfaes@bryangarnier.com Sector Team: Loïc Morvan Antoine Parison Cédric Rossi Virginie Roumage

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY

Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

NEUTRAL

Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

SELL

Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 55.7%

NEUTRAL ratings 32.9%

SELL ratings 11.4%

Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No
		I .	

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London		
Beaufort House		
15 St. Botolph Street		
London EC3A 7BB		
Tel: +44 (0) 207 332 2500		
Fax: +44 (0) 207 332 2559		
Authorised and regulated by the		
Financial Conduct Authority (FCA)		

Paris 26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01 Regulated by the Financial Conduct Authority (FCA) and the Autorité de Contrôle prudential et de

resolution (ACPR)

New York 750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member

Munich Widenmayerstrasse 29 80538 Munich Germany +49 89 2422 62 11

New Delhi The Imperial Hotel Janpath New Delhi 110 001 Tel +91 11 4132 6062 +91 98 1111 5119 Fax +91 11 2621 9062 Geneva rue de Grenus 7 CP 2113 Genève 1, CH 1211 Tel +4122 731 3263 Fax+4122731 3243 Regulated by the FINMA

Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report. Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.